• Profile

Rectal indomethacin to prevent pancreatitis after extracorporeal shock wave lithotripsy (RIPEP): A single-center, double-blind, randomized, placebo-controlled trial

The Lancet: Gastroenterology & Hepatology Feb 12, 2022

Findings demonstrate the efficacy as well as safety of preprocedural rectal indomethacin administration in decreasing the incidence of post-extracorporeal shock wave lithotripsy (ESWL) pancreatitis.

  • This double-blind, randomized, placebo-controlled trial included 1,370 patients aged 18 years or older with chronic pancreatitis and pancreatic stones (>5 mm in diameter) who were eligible for treatment with ESWL.

  • Participants were randomized to receive 100 mg rectal indomethacin or identical glycerin (placebo) suppositories 30 min before ESWL.

  • In the rectal indomethacin and placebo groups, post-ESWL pancreatitis developed in 9% and in 12% of the patients, respectively (relative risk 0·71).

  • Transient adverse events occurred in 34% and 37% of the patients in the rectal indomethacin group and placebo group, respectively, with asymptomatic hyperamylasemia being the most common (28% vs 29%).

  • The incidence of other complications and transient adverse events did not differ between groups.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen